KBY Biotech Indexv0.0.34
Search
← Pipeline|ITA-4515

ITA-4515

Phase 3
By Italfarmaco
Source: Trial-derived·Trials: 2
Modality
Bispecific Ab
MOA
CFTRmod
Target
CD47
Pathway
JAK/STAT
Huntington's
Development Pipeline
Preclinical
~Sep 2020
→ ~Dec 2021
Phase 1
~Mar 2022
→ ~Jun 2023
Phase 2
~Sep 2023
→ ~Dec 2024
Phase 3
Mar 2025
→ Apr 2025
Phase 3Current
NCT08260689
2,939 pts·Huntington's
2025-03→TBD·Active
NCT07205285
2,189 pts·Huntington's
2025-06→2025-04·Active
5,128 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-04-1012mo agoPh3 Readout· Huntington's
Trial Timeline
Q2
P3
Active
P3
Active
Catalysts
Ph3 Readout
2025-04-10 · 12mo ago
Huntington's
Active|StartCompletionToday
Trials (2)
NCTPhaseIndicationStatusNEP
NCT08260689Phase 3Huntington'sActive2939PANSS
NCT07205285Phase 3Huntington'sActive2189Biomarker
Competitors (10)
DrugCompanyPhaseTargetMOA
LLY-8903Eli LillyPreclinicalCD47HER2
LLY-4358Eli LillyPhase 3B7-H3CFTRmod
GelinaritideAbbViePreclinicalFcRnCFTRmod
GSK-4334GSKPreclinicalCD47WRNi
MotainavolisibAmgenNDA/BLACD47PD-L1i
DarafutibatinibBioNTechPreclinicalPRMT5CFTRmod
ALN-8757AlnylamPreclinicalTIGITCFTRmod
BMR-1165BioMarinPhase 2CD47TYK2i
INC-2432IncytePhase 2CD47CGRPant
CevifotisoranNeurocrineApprovedCD47PARPi